Apr 2, 2019
The innate ability of antibodies to bind their targets with high affinity and exquisite specificity is leveraged in the discovery of therapeutic antibodies to treat a broad range of diseases including cancer, autoimmune disease and heart disease.
In addition, antibodies are commonly used as companion diagnostics and reagents to support the therapeutic pipeline and to probe antigenic surfaces to inform vaccine design.
This episode reviews the current and emerging label-free biosensor tools that are used to characterise the binding interactions of antibodies in terms of their kinetics, affinities and epitope specificities from early stage screening to the clinic, with emphasis on throughput.
Original article by Dr Yasmina Noubia Abdiche, Chief Scientific Officer at Carterra
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: